Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

14 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

    Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NVvheIhrTnWwY4Tpc44hSXO|YYm= MXSwMlUwOS9{LkWg{txO M4\zb|MhcA>? MYLy[YR2[2W|IITo[UBj[XOjbDDDRkB1gXKxc3nu[UBxcG:|cHjvdplt[XSrb36gcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mm\rNlYxQTd6N{O=
T24 BC  MnfaR4VtdCCYaXHibYxqfHliQYPzZZk> MlnxNE42NzFxMj61JO69VQ>? NXT1eolYOjRiaB?= MX;lcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>? NWjNNlBEOjZyOUe4O|M>
T24 BC  NFPvR4tCeG:ydH;zbZMhSXO|c3H5 NFjscVMzNjVizszN MnfPNlQhcA>? MkX2d4Vve2m2aYrld{BDSyClZXzsd{B1dyC|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?= MnLNNlYxQTd6N{O=
HepG2 NXLMNFZTTnWwY4Tpc44hSXO|YYm= MVGyNOKh|ryP MWCyOOKhcA>? NXOycHhneHKxZIXj[ZMh[W5iaX70[Y5{\SCleYTvdIxie22rYzD2ZYN2d2yrenH0bY9vKGOxcoLld5BwdmSrbnegeI8h[SCwb4ThZoxmKGSrbHH0ZZRqd25ib3[geIhmKEWUIHPpd5Rmem6| M{T1NVI2QTN2MkOy
U-87 MG  NHLkXXFHfW6ldHnvckBCe3OjeR?= Mm[1NlDDqM7:TR?= NWnJS5lEOjUEoHi= NXuyXXZbcW6lcnXhd4V{KGSxdXLs[U1u\W2kcnHu[UBjd3WwZDDzeJJ2[3S3cnXz NU\qTGNUOjV7M{SyN|I>
HepG2 NYf6O4d5TnWwY4Tpc44hSXO|YYm= M{\0T|IxyqEQvF2= NVryfGlXPi9{NDDo NI\KWnJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? Mkj4NlU6OzR{M{K=
U-87 MG  MWHGeY5kfGmxbjDBd5NigQ>? Mn33NlDDqM7:TR?= Moe0Ok8zPCCq NITEVWdqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDMR|MuUUliY3;0doVifGWmIIfpeIghS1F? NEnCeVAzPTl|NEKzNi=>
HepG2 M1riT2Z2dmO2aX;uJGF{e2G7 MWeyNOKh|ryP NFnNR2E3NzJ2IHi= Mnvn[IVkemWjc3XzJGxEOy2LSTDk[Ydz[WSjdHnvcuKh\nKxbTC2JIg> MW[yOVk{PDJ|Mh?=
U-87 MG  MmjlSpVv[3Srb36gRZN{[Xl? M2TmR|IxyqEQvF2= MU[2M|I1KGh? MWnpcoNz\WG|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS|IITobZMh\my3eDDheEAzPGh? NXjMd2NtOjV7M{SyN|I>
HepG2 NG\iPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;H[HQzOC92MDFOwG0> NUPZWIhYOjRxNEigbC=> MknpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlTmNlU6OzR{M{K=
U-87 MG  NEXPTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETHd5czOC92MDFOwG0> MlvpNlQwPDhiaB?= NGPpe|dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M2fKPVI2QTN2MkOy
A549 M3\sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv2NE4{NTFyIN88US=> MYCyOE84OiCq MkHVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2L5PVI2Pjl5OEm5
H460 M1zO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjkbmRXOC5|LUGwJO69VQ>? MYSyOE84OiCq NUD6SFc{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NGPwS3czPTZ7N{i5PS=>
A549 M{PhNWFxd3C2b4Ppd{BCe3O|YYm= MY[xM|Mh|ryP MVi0PEBp NWrUSooycW6mdXPld{BieG:ydH;zbZM> MmnBNlU3QTd6OUm=
H460 NFnDc4RCeG:ydH;zbZMhSXO|c3H5 M4XjPFEwOyEQvF2= MkXwOFghcA>? NEnzNW1qdmS3Y3XzJIFxd3C2b4Ppdy=> NUOzR2hiOjV4OUe4PVk>
A549 MoKySpVv[3Srb36gRZN{[Xl? NVfaN5RCOyEQvF2= NYL3[ldjQCCq MnqwZoxw[2u|IFHLWEBi[3SrdnH0bY9v NFLnPWIzPTZ7N{i5PS=>
H460 NHPQd4hHfW6ldHnvckBCe3OjeR?= Ml[3N{DPxE1? NEHUV4M5KGh? NUnSVYUx[myxY3vzJGFMXCCjY4TpeoF1cW:w MYGyOVY6Pzh7OR?=
A549 NInIb2ZHfW6ldHnvckBCe3OjeR?= M3HrPVMh|ryP MWi4JIg> MnrEZoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ NYTvWINyOjV4OUe4PVk>
H460 MnT3SpVv[3Srb36gRZN{[Xl? NGOye3c{KM7:TR?= NYGwZ2Y5QCCq MnvZZoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ MYGyOVY6Pzh7OR?=
RMG1 NFq1d21E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGnJO2MyNTNyIN88US=> MXK3NkBp Mluz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MnLNNlU2OTlzNEi=
RMG2 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M37LUVEuOzBizszN NGr4U3U4OiCq MVfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4[3[VI2PTF7MUS4
KOC7C NVLzNHpNS2WubDDWbYFjcWyrdImgRZN{[Xl? NVzN[XRiOS1|MDFOwG0> NF;FNWo4OiCq NIDiU3Rl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Ml7rNlU2OTlzNEi=
HAC2 M{nL[WNmdGxiVnnhZoltcXS7IFHzd4F6 MVuxMVMxKM7:TR?= NFixS2M4OiCq MnK2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NHKxWFgzPTVzOUG0PC=>
RMG2 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUCxMVMxKM7:TR?= NFGzcXI1QCCq MUfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2i4UFI2PTF7MUS4
OVISE Ml3KR4VtdCCYaXHibYxqfHliQYPzZZk> NVeybGNjOS1|MDFOwG0> MlnlOFghcA>? MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXqyOVUyQTF2OB?=
SKOV3 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn7YNU0{OCEQvF2= NYPRc21HPDhiaB?= MnzE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MnzlNlU2OTlzNEi=
A2780 Moq3R4VtdCCYaXHibYxqfHliQYPzZZk> NYLzd|I2OS1|MDFOwG0> Ml;FOFghcA>? M3rLR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHPVS3EzPTVzOUG0PC=>
RMG1 MWPBdI9xfG:|aYOgRZN{e2G7 NFO4SZU{OCEQvF2= MnH4NlQhcA>? MlzBbY5lfWOnczDhdI9xfG:|aYO= MnLtNlU2OTlzNEi=
RMG2 MkPCRZBweHSxc3nzJGF{e3OjeR?= MliwN|Ah|ryP MV2yOEBp M{nlS4lv\HWlZYOgZZBweHSxc3nz MUmyOVUyQTF2OB?=
HCC1806 NGjwXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LaOFAuOTBizszN NXzCWnlLPDhiaB?= NHrROFJGSzVyPUKuPFTjiIoEsfMAjVAvODdizszN NETBV40zPTJ7M{W3Oi=>
MDA-MB-231  M1z2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES1PHoxNTFyIN88US=> NYfxcGRxPDhiaB?= M4fTRmVEPTB;MT6xN-KBkcLz4pEJNE4xPyEQvF2= NWPWdlBLOjV{OUO1O|Y>
GL-1 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljPNE4y6oDVMUCw5qCK|ryP MUG0PEBp M1\0NWlEPTB;OT65NUDPxE1? NYHWZoFvOjR6OEG1NFg>
CLBL-1 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjEV44xNjIkgKOxNFDjiIoQvF2= NXPWUWFOPDhiaB?= MW\JR|UxRTN|LkCg{txO M{DBO|I1QDhzNUC4
UL-1 NEPrSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrw[WYxNjIkgKOxNFDjiIoQvF2= MlyxOFghcA>? MYfJR|UxRTdwMEGg{txO MmXPNlQ5QDF3MEi=
Ema MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXPNE4y6oDVMUCw5qCK|ryP NFvyfVY1QCCq MXzJR|UxRTV6Lkeg{txO NH:0RVgzPDh6MUWwPC=>
PANC-1 NYniTnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHPdIgxNTJ3IN88US=> NUDWNW1JPzJiaB?= M1:ybIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MUCyOFUyQTd3MR?=
MIA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvOelk4OC1{NTFOwG0> NXTvWlNoPzJiaB?= M4XXZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NXHvXlRmOjR3MUm3OVE>
AsPC-1 MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TxRlAuOjVizszN NXXoSm1qPzJiaB?= M4rkZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIro[XczPDVzOUe1NS=>
PANC-1 M3zLcGZ2dmO2aX;uJGF{e2G7 M2jYOVAvPSEQvF2= M4rGUlI1KGh? M2PrPYlvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? MnnwNlQ2OTl5NUG=
MIA MWfGeY5kfGmxbjDBd5NigQ>? MV[wMlUh|ryP MX[yOEBp MYrpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> NG\nZoozPDVzOUe1NS=>
AsPC-1 M3PXR2Z2dmO2aX;uJGF{e2G7 Mn;CNE42KM7:TR?= MYqyOEBp NH\zPYRqdmirYnn0d{BCc3RuIGO2T|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB? M1;KeFI1PTF7N{Wx
U87MG M3PXZmNmdGxiVnnhZoltcXS7IFHzd4F6 M1LxTFAuOjVizszN MnLsNlQuQTZiaB?= NGHrR3Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NVnkdGY{OjRyNkW1NlI>
SGC7901  MYTGeY5kfGmxbjDBd5NigQ>? NF3sWlcxNjd3L{GwxsDPxE1? NGjwOpA1QCCq MXHk[YNz\WG|ZYOgdE1Cc3RiKGPldkA1PzNrLDDwMWdUUzQQsjCoV4VzKDlrLDDhcoQhSy2PWVOgcIV3\Wy|wrC= M{DofVI{QTF{MkS2
MGC803  NXvsR2htTnWwY4Tpc44hSXO|YYm= MYOwMlc2NzFywrFOwG0> MmnXOFjDqGh? M4\0ZoRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=> MX[yN|kyOjJ2Nh?=
TykNu NIHadoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3dGp5UUN3ME2zMlUh|ryP NWO0PGtvOjN6N{ewNVI>
TykNuR NWC0UpBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLFW5ZPUUN3ME21MlUh|ryP Mnr4NlM5PzdyMUK=
M41 M2rXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITVe3NKSzVyPUK0Mlch|ryP MWKyN|g4PzBzMh?=
M41R NX\3W2tST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jsV2lEPTB;MUmuPEDPxE1? NWPMdZpHOjN6N{ewNVI>
OVCAR8 NVnZPJVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:4ZY9mUUN3ME2zNU4yKM7:TR?= NV6zZY5DOjN6N{ewNVI>
HeyA8 M3\hTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLlPZhKSzVyPUK0MlMh|ryP MUWyN|g4PzBzMh?=
A2780CP NXfTbnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTdwNjFOwG0> NU\UfZVKOjN6N{ewNVI>
OVCAR5 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXDTWM2OD14Lkeg{txO MVSyN|g4PzBzMh?=
A2780S NUDwR4U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TzVmlEPTB;MUSuOUDPxE1? MWeyN|g4PzBzMh?=
MCAS NVn6UII2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzqTWM2OD1zMj61JO69VQ>? M33LZVI{QDd5MEGy
NCI-H727 MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M33UT|AuOTByIN88US=> NHPISoQzPC95MjDo NXq2R|B6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NG[xUmQzOjR7OUSzOy=>
GOT1 NF\aSXNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVPVd2d6OC1zMECg{txO NXjZSYF3OjRxN{KgbC=> M3zadYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MmTBNlI1QTl2M{e=
BON1 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{DPWVAuOTByIN88US=> NUPHUlNyOjRxN{KgbC=> NVLUNIg{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MWiyNlQ6QTR|Nx?=
BON1 MlPrRZBweHSxc3nzJGF{e3OjeR?= MnXzNE0yOCEQvF2= M{fPXlI1KGh? NYm3cnZjcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NH7UOYEzOjR7OUSzOy=>
BON1 NYnKeWVYTnWwY4Tpc44hSXO|YYm= MVi3MlUwOTBizszN MVq4JIg> Mlzy[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJRp\SCjboTpMYFxd3C2b4TpZ{Bxem:2ZXnud{BDS0x{IHHu[EBD[2xvWFy= M4TONFIzPDl7NEO3
Kasumi-1 NGjZO|hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHraW3UxNTJyIN88US=> MYWyOE81QCCq MlPX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NUDYU5FpOjJ2MEeyNlg>
HL-60 NXrjUZFYS2WubDDWbYFjcWyrdImgRZN{[Xl? NF\EV4UxNTJyIN88US=> M13CdFI1NzR6IHi= NEnEXI9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NEC2Ro8zOjRyN{KyPC=>
Kasumi-1 NWP2VGtKSXCxcITvd4l{KEG|c4PhfS=> Mn\vNVAh|ryP NWTrZ2c1OjRiaB?= M3vHVolv\HWlZYOgZZBweHSxc3nz M4ezbVIzPDB5MkK4
HL-60 M3Pt[2Fxd3C2b4Ppd{BCe3O|YYm= M1jDPFExKM7:TR?= NH25NnQzPCCq Mk\YbY5lfWOnczDhdI9xfG:|aYO= M{PUUlIzPDB5MkK4
Kasumi-1 NH7Qd5hHfW6ldHnvckBCe3OjeR?= M2DrcFIvPS93L{GwJO69VQ>? NHTTbIozPCCq NIi1RVRl\WO{ZXHz[ZMhSWu2IHHu[EBxNUGtdDDs[ZZmdHQEoHTvd4Uu\GWyZX7k[Y51dHl? M4\x[FIzPDB5MkK4
HL-60 NVf4d4FjTnWwY4Tpc44hSXO|YYm= MnGyNk42NzVxMUCg{txO MYKyOEBp MVLk[YNz\WG|ZYOgRYt1KGGwZDDwMWFsfCCuZY\lcJPDqGSxc3Wt[IVx\W6mZX70cJk> NHjhcIYzOjRyN{KyPC=>
Kasumi-1 MYDGeY5kfGmxbjDBd5NigQ>? MWSyMlUwPS9zMDFOwG0> MlP4NlQhcA>? M1nvOYlv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MlL0NlI1ODd{Mki=
HL-60 MXvGeY5kfGmxbjDBd5NigQ>? NHjkTlEzNjVxNT:xNEDPxE1? NFjCZ5IzPCCq MXjpcoR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NIm2NZgzOjRyN{KyPC=>
K562 MXTGeY5kfGmxbjDBd5NigQ>? MXWyNEDPxE1? M4\meVQ5KGh? Mki2bY5lfWOnczDheZRweGijZ4pCpC=> NGnMU3AzOjRyN{KyPC=>
OCUT1 NGTw[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonSNE4yNTNizszN Mkj2OUBl M1\KdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFfIboEzOjB7MEK3NS=>
K1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXVNE4yNTNizszN NIjKO2E2KGR? NWTjfnlLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHLqeXQzOjB7MEK3NS=>
OCUT1 M2XxZWZ2dmO2aX;uJGF{e2G7 NUixdVJIOyEQvH2= NFzTNmMzPCCq NGXRSJpk[XW|ZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBqdiCJMj;NJJBp[XOn MYGyNlA6ODJ5MR?=
CaOV3 Mln6R4VtdCCYaXHibYxqfHliQYPzZZk> MXexM|UwOTBizszN MVS0PEBp NI\kR|Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYKgZ491emWjdHXkJJdqfGhicHHjcIl1[XinbB?= M2HrUlIyPzd3MEW0
SKOV3 NXvKTHJJS3m2b4TvfIlkcXS7IFHzd4F6 MWW1JO69VQ>? NW\6SWwzPDhiaB?= Mn3m[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> MViyNVc4PTB3NB?=
A2780 MWjDfZRwfG:6aXPpeJkhSXO|YYm= MXK1JO69VQ>? MnXXOFghcA>? NY\EcWRn\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MX[yNVc4PTB3NB?=
HT-29  MVnDfZRwfG:6aXPpeJkhSXO|YYm= MYe1JO69VQ>? NUi3bml6PDhiaB?= NVv0PGhl\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MYiyNVc4PTB3NB?=
A498 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW0bFExNTRyIN88US=> NXTLcm1qPzJiaB?= MljUbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MVWyNVY1PDB3MB?=
CAKI-1 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjrT5gxNTRyIN88US=> MWq3NkBp NXXReZBXUUN3MI6xNEDPxE1? NF\UNIgzOTZ2NEC1NC=>
769-P MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG4NE01OCEQvF2= MWi3NkBp MVTJR|UxhjVvMUCg{txO M1vKc|IyPjR2MEWw
786-0 NEft[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXNE01OCEQvF2= M17FTlczKGh? MUTJR|UxhjVizszN M1HHblIyPjR2MEWw
786-O MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMVIxKM7:TR?= MkTpO|IhcA>? M{DWUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NH34OI0zOTZ2NEC1NC=>
CAKI-1 M4S3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTEOIwxNTJyIN88US=> NXfkZWRDPzJiaB?= NF7Lb2dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MVWyNVY1PDB3MB?=
769-P M4m4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDtNGMxNTJyIN88US=> M2DBcVczKGh? NX;sbHppcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NU[wWpVKOjF4NESwOVA>
A498 M4XTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TCOlAuOjBizszN NFW2XlU4OiCq MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHPjd28zOTZ2NEC1NC=>
CWR22RV1 MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M13GWlExKM7:TR?= NYeydIx7OjRiaB?= MXfpcoNz\WG|ZYOgd4Vve2m2aY\peJkhd2ZiaIXtZY4hS1eUMkLSWlEh[2WubIOgeI8hemGmaXH0bY9v M4TrNFIyPDl4Mkez
CWR22RV1 NIX3RYhCeG:ydH;zbZMhSXO|c3H5 NYfP[m5zOTBizszN M3nQeVI1KGh? MVjlcohidmOnczDyZYRq[XSrb36gbY5lfWOnZDDhdI9xfG:|aYO= Moj1NlE1QTZ{N{O=
CWR22RV1 NYToPGhKTnWwY4Tpc44hSXO|YYm= Ml33OUDPxE1? MYWyOEBp M3XKcZJm\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGFsfCC|aXfubYZq[2GwdHz5 MlzxNlE1QTZ{N{O=
HepG2  NICxZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjaWmZLPS9zMD:yNE81OCEQvF2= M37BTlI1NzR6L{eyJIg> M1ywPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NXOzRpZJOjB6NEK0NlU>
Bel-7402 NH3WU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPiOU8yOC9{MD:0NEDPxE1? MlPwNlQwPDhxN{KgbC=> MoH0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGT1b5EzODh2MkSyOS=>
HepG2  MkXuSpVv[3Srb36gRZN{[Xl? NFP2VoU2NzFyL{KwJO69VQ>? MmjSNlQhcA>? MWry[ZN2dHS|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V? NYrPRWhlOjB6NEK0NlU>
Bel-7402 MonZSpVv[3Srb36gRZN{[Xl? MYi1M|ExNzJyIN88US=> Ml3uNlQhcA>? MlLwdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn M1LQVlIxQDR{NEK1
HepG2  NGTa[ItCeG:ydH;zbZMhSXO|c3H5 MnvuOU8yOC9{MDFOwG0> NGrEOlQzPC92ODDo NHfLNYdqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl MnTJNlA5PDJ2MkW=
Bel-7402 MnrVRZBweHSxc3nzJGF{e3OjeR?= M3TQdFUwOTBxMkCg{txO MoPyNlQwPDhiaB?= MYXpcoR2[2W|IHHwc5B1d3OrczDheEB1cGVibH;u[{11cW2nIHX4dI9{fXKn MVOyNFg1OjR{NR?=
OAW-42 NYL0N3hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2RW56OC12MDFOwG0> MWq3NuKhcA>? M{XOcmlEPTC-MUCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3TiO|IxPDB3Mkm2
PA-1  NYO2b3J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TwTlAuPDBizszN M{\2XlczyqCq M{PPSWlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4XSPFIxPDB3Mkm2
SKOV3  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TEOFAuPDBizszN NYTxenRbPzMEoHi= MUPJR|UxhjNyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2Xpb|IxPDB3Mkm2
A2780 M4fidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS3NE0zOCEQvF2= MoruOFgwPzJiaB?= MULJR|UxyqB;wrCzxsDPxG1? Mo\RNlA1ODV{OU[=
A2780cis  MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zJPVAuOjBizszN M1XEUFQ5Nzd{IHi= NGXPNohKSzVywrC9xsA3yqEQvH2= M4D2b|IxPDB3Mkm2
SKW6.4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXixd24{Oi1zMNMg{txO NFOx[3M1QMLiaB?= NFe2OZRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MX[yNFE{ODl4MB?=
MAVER MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLVcnBZOi1zMNMg{txO NYfGSms6PDkEoHi= MlrRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mly5NlAyOzB7NkC=
BJAB M2fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[yMVExyqEQvF2= M4K4ZVQ5yqCq MlnEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4jIbVIxOTNyOU[w
OCI MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jYTVIuOTEEoN88US=> NFzmNlQ1QMLiaB?= MlPTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NWLuOmJFOjBzM{C5OlA>
MOLM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHVNWIzNTFywrFOwG0> MkSyOFjDqGh? NET2WJBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mm\JNlAyOzB7NkC=
HL-60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjO[WtEOi1zMNMg{txO MoTmOFjDqGh? NUDmXG4zcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWXvSodFOjBzM{C5OlA>
SKW6.4 Mkj0RZBweHSxc3nzJGF{e3OjeR?= M2D0[VExyqEQvF2= M4nlSVI1NzR6IHi= MmjEbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= M13HfFIxOTNyOU[w
MAVER MkXwRZBweHSxc3nzJGF{e3OjeR?= NVvoR4VGOTEEoN88US=> M{PMR|I1NzR6IHi= M3z6XYlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MXiyNFE{ODl4MB?=
BJAB MoLrRZBweHSxc3nzJGF{e3OjeR?= NF3pZ|AyOMLizszN MnezNlQwPDhiaB?= MX\pcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 MnLWNlAyOzB7NkC=
OCI M2i3UWFxd3C2b4Ppd{BCe3O|YYm= MoLRNVDDqM7:TR?= M4exT|I1NzR6IHi= NVXGR3k5cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NIju[WczODF|MEm2NC=>
MOLM MYLBdI9xfG:|aYOgRZN{e2G7 M2n6NFExyqEQvF2= NHrad5YzPC92ODDo M3f0SYlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= NV7WT5VLOjBzM{C5OlA>
HL-60 MofmRZBweHSxc3nzJGF{e3OjeR?= NXvodWhWOTEEoN88US=> MYGyOE81QCCq MnXrbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= NX\iXXRQOjBzM{C5OlA>

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID